NASDAQ$BVS
Bioventus Inc - A · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Bioventus reported Q1 2026 net sales of $132.1M with net income of $3.9M.
Net sales increased to $132.1 million from $123.9 million. Net income was $3.9 million versus a $3.3 million loss a year ago as orthobiologics and pain treatment volumes improved.
- Net sales $132.1M (+7% YoY).
- Net income $3.9M vs $(3.3)M loss prior year.
- Surgical and non-surgical orthopedics mix.
- Cash pay and clinic channel growth.
Headline financials
Revenue & EPS history
Bioventus · Revenue · Quarterly
$132M
Forward guidance
Management discusses product launches, reimbursement, and clinic partnerships.
Tailwinds
- Returned to profitability year over year.
- Mid-single-digit sales growth.
Headwinds
- Reimbursement and payer coverage variability.
- Competition in joint preservation therapies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
+2.1%
Avg return
Earnings day
+5.6%
Avg return
5 days after
+13.1%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+26.0%
Q1 2024
Best reaction
-39.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.2% | -4.6% | -15.4% | |
| Q4 2025 | +7.4% | +4.6% | +5.9% | |
| Q3 2025 | +15.1% | +13.6% | +16.2% | |
| Q1 2025 | -12.0% | -5.0% | -7.4% | |
| Q4 2024 | +23.3% | +9.7% | -13.6% | |
| Q3 2024 | -17.7% | -13.8% | -15.1% | |
| Q2 2024 | +19.2% | +21.2% | +54.3% | |
| Q1 2024 | +26.0% | +35.0% | +70.0% | |
| Q4 2023 | -0.4% | +2.6% | -9.4% | |
| Q3 2023 | +6.0% | -2.1% | +42.1% | |
| Q2 2023 | +20.3% | +32.9% | -2.6% | |
| Q1 2023 | +6.5% | +58.5% | +195.9% | |
| Q4 2022 | -6.6% | +2.5% | -16.5% | |
| Q3 2022 | -39.9% | -42.7% | -18.9% | |
| Q2 2022 | +4.8% | +3.9% | -6.4% | |
| Q1 2022 | -9.1% | +4.5% | +12.5% | |
| Q4 2021 | +0.8% | -3.0% | -4.0% | |
| Q3 2021 | -0.5% | -4.5% | -18.7% | |
| Q2 2021 | +1.7% | +0.3% | -0.7% | |
| Q1 2021 | +1.0% | +3.3% | +17.0% | |
| Q4 2020 | -4.8% | -0.4% | -9.1% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro